View printer-friendly version |
Charles River and PathoQuest Strengthen Strategic Partnership
PathoQuest establishes
The expanded relationship between PathoQuest and Charles River will offer North American biotechnology companies a NGS testing facility in the
Construction of PathoQuest’s new office and laboratory facility is scheduled to begin in late 2020 with NGS services expected to be available in 2021. Once complete, the lab will be aligned with PathoQuest’s existing lab in
Charles River’s
Approved Quotes
-
“The addition of a PathoQuest facility at the
Wayne site highlights our commitment to addressing our clients’ dynamic needs. PathoQuest’s NGS-based testing solution provides a rapid, reliable and comprehensive testing solution, and now, clients will have it at their fingertips through this expanded partnership.” –Birgit Girshick , Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River -
“Our NGS-based approach provides a state-of-the-art quality control testing solution for biopharmaceutical quality assurance and production managers. Our new facility in
Wayne will create additional opportunities to integrate with Charles River’s service offerings and expose more pharmaceutical and biotechnology groups to our technology, furthering the rapid expansion of our business.” – Jean-Francois Brepson, President and CEO, PathoQuest
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
About PathoQuest
PathoQuest as pharmaceutical establishment offers biopharmaceutical companies a game changing Genomic QC testing to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and recombinant. It enables the ability to reduce the turnaround time for safety testing, replacing traditional methods like animal testing. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation process completed by proprietary pathogen genome sequence databases and automated analysis pipeline.
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR). For more information about PathoQuest, visit www.pathoquest.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005153/en/
Investor Contact for PathoQuest:
Patrick COURT
CFO
finance@pathoquest.com
Media Contact for PathoQuest:
Ophélie PHILIPOT
ophelie.philipot@comopi.tech
Investor Contact for Charles River:
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com
Media Contact for Charles River:
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com
Source: Charles River